Silex Systems Limited · ASX:SLX
Silex Systems — Investor Presentation (July 2023)
20 slides from Silex Systems's investor presentation, Jul 26, 2023
Slide 1: ASX announcement cover note: Investor Presentation
Investor Presentation 26 July 2023 Silex Systems Limited (Silex) (ASX: SLX) (OTCQX: SILXY) is providing the attached presentation to support upcoming Investor Relations activities, including a presentation by Dr Michael Goldsworthy, Silex CEO to Canaccord today. Dr Goldsworthy will be accompanied to
Slide 2: Silex Systems Limited Investor Presentation
Silex Systems Limited For personal use only Investor Presentation (ASX: SLX) (OTCQX: SILXY) Dr Michael Goldsworthy CEO/Managing Director 26 July 2023 www.silex.com.au 1
Slide 3: Forward Looking Statements and Risk Factors
Forward Looking Statements and Risk Factors About Silex Systems Limited (ASX: SLX) (OTCQX: SILXY) Silex Systems Limited ABN 69 003 372 067 (Silex or Company) is a technology commercialisation company whose primary asset is the SILEX laser enrichment technology, originally developed at the Company’s
Slide 4: Our Mission: commercialise SILEX laser enrichment technology
Our Mission: to commercialise the unique SILEX laser enrichment technology for application to: For personal use only Uranium production Silicon enrichment Other potential markets and enrichment (silicon quantum computing) (e.g. medical isotopes) (nuclear power) Our strategy is focused on extracting
Slide 5: Investment Focus – Strong ESG Credentials
Investment Focus – Strong ESG Credentials Investment in three key growth industries with strong ESG credentials: 1) Nuclear Power for Clean Energy – potential to support Net-Zero 2050 targets with carbon-free electricity production 2) Next Generation Quantum Computing – expected to help solve global
Slide 6: Focus on Commercialisation
Focus on Commercialisation Uranium production and enrichment For personal use only (nuclear power) • SILEX uranium technology licencee Global Laser Enrichment (GLE) is actively progressing towards commercialisation • US-based GLE under JV ownership since 2021: 51% by Silex and 49% by Cameco Corporat
Slide 7: Nuclear Fuel Supply and Emerging Threats
Nuclear Fuel Supply and Emerging Threats The Nuclear Fuel Supply Chain For personal use only Emerging Threats to the Global Nuclear Fuel Supply Chain: - Supply chain risks exposed by over-dependence on Russian-sourced nuclear fuel - Western supply – curtailments and under-investment in resources and
Slide 8: US and EU Nuclear Fuel Requirements Supplied by Russia
US and EU Nuclear Fuel Requirements Supplied by Russia Russian Share of Global EU Nuclear Fuel US Nuclear Fuel Production Capacity1 Supplied by Russia2 Supplied by Russia1,3 Uranium (U308) ~14% ~20% ~14% For personal use only Conversion ~27% ~25% ~18% Enrichment (SWU) ~45% ~31% ~24% 1. WNA and UxC,
Slide 9: US Uranium and Enrichment Vulnerability
US Uranium and Enrichment Vulnerability US currently imports the vast majority of its nuclear fuel: - 95% of its uranium requirements (including ~14% from Russia) - 100% of its conversion requirements (including ~18% from Russia) For personal use only - 70% of its enriched uranium requirements (incl
Slide 10: Emerging Nuclear Fuel Supply Opportunities for GLE
Emerging Nuclear Fuel Supply Opportunities for GLE Million SWU Uncovered SWU Base Case Demand © UxC Uncovered Uranium Base Case Demand © UxC 250 90 225 80 200 70 For personal use only 175 60 150 50 125 Non-U.S. Utilities 40 Non-U.S. Utilities 100 United States United States Total Requirements 30 75
Slide 11: Recent Nuclear Fuel Market Price Trends
Recent Nuclear Fuel Market Price Trends Uranium Price Conversion Price US$/SWU Enrichment (SWU) Price US$/lb US$/kgU $70.00 $45.00 $160.00 U3O8 LT U3O8 NA NA LT Spot LT SWU Spot Conv Conv SWU $40.00 $140.00 $60.00 $35.00 $120.00 $50.00 For personal use only $30.00 $100.00 $40.00 $25.00 $80.00 $30.00
Slide 12: Acceleration of GLE's CY2023 Activities for SILEX technology
Acceleration of GLE’s CY2023 Activities for SILEX technology GLE has unique potential to address the ‘Triple Opportunity’ emerging in the global nuclear fuel supply chain: • GLE joint venture owners Silex (51%) and Cameco (49%) have agreed to a plan and budget for CY2023 that accelerates activities
Slide 13: GLE's Potential Timelines for Commercialisation of SILEX technology
GLE’s Potential Timelines for Commercialisation of SILEX technology1 For personal use only www.silex.com.au 12
Slide 14: GLE's Multi-Purpose PLEF Production Plant Opportunity
GLE’s Multi-Purpose PLEF Production Plant Opportunity The PLEF Triple Opportunity Paducah Laser Enrichment Facility (PLEF) commercial project to deploy the SILEX technology in the US: • PLEF UF6 Production: Production of up to 5 million pounds natural grade uranium (as UF6) annually for up to 30 yea
Slide 15: GLE's Multi-Purpose PLEF Production Plant Opportunity
GLE’s Multi-Purpose PLEF Production Plant Opportunity For personal use only Source: GLE, Multi-purpose PLEF (indicative) www.silex.com.au 14
Slide 16: PLEF UF6 Production Opportunity
PLEF UF6 Production Opportunity (Natural UF6 production from tails) Target Commercial Akin to a ‘Tier 1’ Uranium Resource* Equivalent U3O8 Operation Date For personal use only Based on low cost and Production Baseline: c. 2030 longevity of production Up to 5 million lbs p.a. for (with potential acce
Slide 17: GLE Value Proposition for Silex
GLE Value Proposition for Silex* 1) GLE Equity – Minimum 25%: • Currently 51% - potentially 25% post-Cameco Option, with payment for 26% at fair market value For personal use only • Significant equity stake in GLE as a potential major nuclear fuel supplier • Attractive business case with Triple Oppo
Slide 18: Significant Additional Opportunities
Significant Additional Opportunities For personal use only Silicon enrichment Other potential markets (silicon quantum computing) (e.g. medical isotopes) • SILEX technology proven capable of producing highly enriched silicon • Newly commenced Medical Isotope Separation Technology project in the form
Slide 19: SILEX Technology Summary
SILEX Technology Summary GLE’s path to market underpinned by the PLEF UF6 project for cost effective production of natural uranium (in the form of UF6) and significant value of the contained conversion component Acceleration of CY2023 activities in the pilot demonstration project creates opportunity
Slide 20: Thank you
For personal use only Thank you 19